Exenatide once weekly suspension

DRUG2 trials

Sponsors

AstraZeneca

Conditions

Diabetes Mellitus, Type 2Diabetes Type 2

Phase 3

Efficacy and Safety of Exenatide Once Weekly Suspension in Subjects With Type 2 Diabetes

CompletedNCT01652716

AstraZenecaDiabetes Mellitus, Type 2

Start: 2013-01-31End: 2014-08-31Updated: 2018-07-03

Comparison Study of the Glycemic Effects, Safety, and Tolerability of Exenatide Once Weekly Suspension to Sitagliptin and Placebo in Subjects With Type 2 Diabetes Mellitus

CompletedNCT01652729

AstraZenecaDiabetes Type 2

Start: 2013-02-28End: 2014-04-30Updated: 2015-08-20

Related Papers

Further improvement in glycemic control after switching from exenatide two times per day to exenatide once-weekly autoinjected suspension in patients with type 2 diabetes: 52-week results from the DURATION-NEO-1 study

BMJ Open Diabetes Research & Care2020-10-014 citations

Safety and Efficacy of Exenatide Once Weekly in Participants with Type 2 Diabetes and Stage 2/3 Chronic Kidney Disease

Diabetes Therapy2020-04-189 citations